Pharmion Corporation (Nasdaq: PHRM) 46% HIGHER; Vidaza significantly extends overall survival by 74% in Phase 3 trial in Myelodysplastic Syndromes.
This article: 362 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE